Advertisement

Topics

Latest "Biomarker discovery Driving technologies" News Stories

01:27 EDT 25th June 2017 | BioPortfolio

Here are the most relevant search results for "Biomarker discovery Driving technologies" found in our extensive news archives from over 250 global news sources.

More Information about Biomarker discovery Driving technologies on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biomarker discovery Driving technologies for you to read. Along with our medical data and news we also list Biomarker discovery Driving technologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biomarker discovery Driving technologies Companies for you to search.

Showing "Biomarker discovery Driving technologies" News Articles 1–25 of 19,000+

Relevant

Biomarker discovery could allow prediction of rheumatoid arthritis outcomes

A biomarker has been found that could make it easier to predict which rheumatoid arthritis patients are at most risk of serious illness. Researchers have discovered that antibodies against the cartilage protein collagen II are associated with better outcomes, and could be helpful in determining the best treatment to use for individual people. Healthcare professionals […] The post Biomarker d...


Philips Launches Informatics Platform to Advance Drug Research & Biomarker Discovery

Today, Philips has announced the launch of Xplore, a web-based image and data management platform that will help pharma and academic researchers speed up drug research and biomarker discovery through enhanced integration, visualization and analytics tools. Xplore v4.0 will be available commercially in July 2017. Customers have the option to purchase the basic package or ... Read More

Insilico Medicine launches personalized drug discovery platform to develop new treatments for ALS

Today, Insilico Medicine, Inc., a company applying the latest advances in deep learning to biomarker development, drug discovery and aging research, launched ALS.AI, a personalized drug discovery and biomarker development platform utilizing the latest advances in deep learning.


Bristol-Myers Squibb and Nordic Bioscience Collaborate for Fibrosis Biomarker Technology

NEW YORK & HERLEV, Denmark–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including Non-alcoholic steatohepatitis (NASH). Nordic Bioscience has over ...

Bristol-Myers Squibb, Nordic Bioscience collaborate on fibrosis biomarker technology

Bristol-Myers Squibb and Nordic Bioscience, a Danish company specializing in biomarker technologies, announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including non-alcoholic steatohepatitis (NASH). Nordic Bioscience has over 25 years’ experience in biomarker development and clinical trials with extensive ...

Bridging the translational innovation gap through good biomarker practice

Few biomarkers progress from discovery to become validated tools or diagnostics. To bridge this gap, three European biomedical research infrastructures — EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking) and ELIXIR (focused on data sharing) — are paving the way to developing and sharing best practices for biomarker validation.

New Clinical and Biomarker Data Validate Immune Design’s Lead Programs and Discovery Platforms

Data from CMB305 and G100 to be Presented at ASCO Annual Meeting in June 2017 SEATTLE and SOUTH SAN FRANCISCO, May 17, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, reported new clinical and biomarker data today from CMB305 and G100 monotherapy studies. The American Society of Clinical Oncology (ASCO) is publishing three ab...

AsiaPacific Next Generation Sequencing NGS market by Product software and services by Technology whole targeted resequencing, genome sequencing, de novo sequencing, exome sequencing, RNASeq, ChIPSeq and MethylSeqby application diagnostics, drug discove

The AsiaPacific NGS market which was worth $ 567.7 million in 2016 is poised to reach$1,636.7 million by 2021 at a CAGR of 23.59%. Asia presents significant opportunities for theinvestors/venture capitalists as the developed markets are saturated. The presence of noteworthydevelopments by China and Japan for integration of new technologies and the development ofhealthcare is majorly driving the As...

ReproCELL and Fox Chase Cancer Center Form Strategic Alliance to Accelerate Biomarker and Genetic Discovery / Alliance provides wider access to oncology biospecimens to accelerate discovery and translational studies

BELTSVILLE, MD and PHILADELPHIA, PA -- (Marketwired) -- 04/13/17 -- ReproCELL and Fox Chase Cancer Center today announced a strategic alliance aimed at accelerating oncology discovery and translat...

Japan Safety Biomarker Workshop

(The Critical Path Institute (C-Path)) The Japan Safety Biomarker Workshop, held February 20-21 at the RIKEN Institute, in Yokohama, Japan, assembles leading scientists and researchers from industry and academia, and government regulatory authorities. Attendees will gain perspective on biomarker development and biomarker application in preclinical and clinical research. Topics include an overview ...

Latest advances in artificial intelligence for drug discovery to be presented at the NVIDIA GTC

(InSilico Medicine, Inc.) Insilico Medicine, Inc, is a big data analytics company specializing in applying the latest advances in deep learning to drug discovery, biomarker development and aging research. In the NVIDIA Graphics Technology Conference (GTC), the scientists from Insilico Medicine will present its latest progress on the applications of Generative Adversarial Networks to Drug Discovery...

Cancer Genetics Is Selected By eFFECTOR To Provide Biomarker Discovery And Development Services For Novel Oncology Drugs

  Life Sciences Jobs   ...

New Clinical And Biomarker Data Validate Immune Design Corporation???s Lead Programs And Discovery Platforms

  Life Sciences Jobs   ...

Human Longevity Announces Agreement With Merck KGaA, Darmstadt, Germany To Engage In Cancer Biomarker Discovery In Advanced Melanoma

  Life Sciences Jobs   ...

Insilico Medicine launches a drug discovery platform ALS.AI

(InSilico Medicine, Inc.) Insilico Medicine with its collaborator, Above & Beyond, launched ALS.AI, launches the personalized drug discovery and biomarker development platform ALS.AI, utilizing the latest advances in deep learning.

North America DNA Sequencing Market Forecast 20172023 [Updated: 04012017] Prices from USD $1250

KEY FINDINGSEurope has the second largest market share of the DNA sequencing market. Factors, which favor growth of DNA sequencing market, are better healthcare infrastructure, awareness about latest technologies, major biotechnology companies being based in this region and government initiatives for increasing research and development. The global DNA sequencing market is poised to grow during the...

Insilico Medicine to present research findings in AI for drug discovery at BioDataWorld West Congress

Insilico Medicine, a Baltimore-based Big Data analytics company applying deep learning techniques to drug discovery, biomarker development and human longevity research will present and chair a panel at the BioDataWorld West, San Francisco, April 26-27.

Europe DNA Sequencing Market Forecast 20172023 [Updated: 04012017] Prices from USD $1250

KEY FINDINGSAsiaPacific market is expected to report good growth in the forecast period due to higher awareness and demand for personalized medicine. Factors, which favor growth of DNA sequencing market, are better healthcare infrastructure, awareness about latest technologies, major biotechnology companies being based in this region and government initiatives for increasing research and developme...

A biomarker could tackle one of worst diseases in sports

Exosome Sciences is investigating a potential biomarker for a rare neurodegenerative disease that has plagued veterans and professional athletes.

NIH SPECIAL Science SERIES: Testing the Efficacy of New Cancer Treatments/Therapies in Clinical Trials using a Unique Biomarker

One Million Solutions in Health™ is working with the NIH to accelerate knowledge and understanding about new treatment options like this unique biomarker which has the potential to predict recurrence and metastasis in various cancers. These technologies are often available for licensing or collaborations. Boston, MA (PRWEB) January 31, 2017 The NIH has produced another novel solution in this un...

Horizon Discovery Signs a Master Service Agreement with Top Three Pharma Company

Cambridge, UK, 14 February 2017: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or the “Group”), the world leader in the application of gene editing technologies, today announces the signing of a Master Services Agreement (MSA) with a top three global pharmaceutical company (the “Company”), extending support for their drug discovery and development efforts to Horizon’s ...

Research results in AI for drug discovery to be presented at the BioDataWorld West in San Francisco

(InSilico Medicine, Inc.) Insilico Medicine, a Big Data analytics company applying deep learning techniques to drug discovery, biomarker development and human longevity research will present new research applying generative adversarial networks to developing new molecular structures for leads in oncology and other diseases at the BioDataWorld West, San Francisco, April 26-27.

FDA approves Merck’s Keytruda for patients who have a specific biomarker

Brian BerkAccording to the agency, this is the first time it has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. read more

Biomarker Traces Glaucoma Development and Progression

A potential biomarker protein has been identified that was elevated in rodent models of glaucoma and in fluid taken from...

Approval for biomarker-based Keytruda a US FDA first

US FDA has approved a cancer treatment based on a common biomarker, as opposed to the location in the body where the tumour developed.


Quick Search
Advertisement
 

News Quicklinks